Neurotechnology like DBS or transcranial magnetic stimulation have clear benefits in diagnosis and therapy and are largely embraced by the medical community. But what about recent accelerated development from tech entrepreneurs to harness cognitive pathways for everyday tasks? This is referred to as brain computer interface technology or BCI. Commercial products such as Neuralink, attempt to implant chips promising to link brain activity with tasks such as accessing phones or cars. This brings up real questions on autonomy, privacy, and medical implications, but is there more to these technological advancements that could provide medical benefit for our patients? We discuss the commercial and medical aspects surrounding BCI technology and the physician and scientist’s role in this rapidly evolving field with Dr. Karen Rommelfanger, the founder and director of the Neuroethics Program at Emory University and now the founder of the world’s first think and DO tank dedicated wholly to neuroethics called the Institute of Neuroethics. She also serves as a member of the BRAIN Initiative’s Neuroethics Working Group and was on the advisory council to the director of the National Institutes of Health (NIH) for BRAIN 2025. Series 4, Episode 1. Featuring:

• Guest: Dr. Karen Rommelfanger, Emory University & Institute of Neuroethics
• Interviewer/Producer: Rohini Samudralwar, University of Pennsylvania